Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARGE: Guselkumab vs Risankizumab in Crohn's Disease
NCT07499232Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Apr 2026; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07499232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499232.